New data from two large studies presented at the 2025 ASCO Gastrointestinal Cancers Symposium (GICS) 2025 provide evidence of the clinical utility of circulating tumor DNA (ctDNA) testing in ...

For years, breast cancer treatment has been guided by genetic alterations found in tumor tissue, typically through invasive biopsies. However, the dynamic nature of cancer and limitations in tissue ...

SAN FRANCISCO -- Circulating tumor DNA (ctDNA) measurements showed promise for identifying patients with early colorectal ...

Serial circulating tumor DNA (ctDNA) testing showed limited clinical benefit in colorectal cancer (CRC) surveillance when frequent imaging is used. The study's retrospective design and small sample ...

Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma. Circulating tumor DNA (ctDNA) is not yet standard practice in ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) ...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Nick Turner, Dr. Isaac Garcia-Murillas and their colleagues at The Institute of Cancer Research, ...